Front Neurol:椭圆形瞳孔研究现状

2019-03-25 不详 网络

英国伦敦国立神经外科医院神经眼科的Bremner FD和美国新泽西州西海岸大学医学中心神经外科的Drapkin AJ两人近日在Front Neurol杂志上发表了一篇重要的综述文章,他们对卵圆形瞳孔的研究现状进行了分析,并阐述了它与瞳孔异位的区别以及它们在临床上的的不同意义。

英国伦敦国立神经外科医院神经眼科的Bremner FD和美国新泽西州西海岸大学医学中心神经外科的Drapkin AJ两人近日在Front Neurol杂志上发表了一篇重要的综述文章,他们对卵圆形瞳孔的研究现状进行了分析,并阐述了它与瞳孔异位的区别以及它们在临床上的的不同意义。

他们进行文献检索,发现有类似这种情况的实例只有20例临床病例。对这些病例的回顾研究,可以加深人们对此类疾病的认识,发现其致病性病变的最有可能的生理结构。作者也进行了深入讨论,对其致病的病理生理学机制进行了一些初步讨论。

原文出处:

Bremner, F.D. and A.J. Drapkin, The Dynamic Oval Pupil. Front Neurol, 2019. 10: p. 75.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-06-16 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-27 小几洁
  5. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-26 医者仁心5538

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2058750, encodeId=bdd52058e500a, content=<a href='/topic/show?id=fcd7e341590' target=_blank style='color:#2F92EE;'>#研究现状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73415, encryptionId=fcd7e341590, topicName=研究现状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Fri Apr 19 06:03:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745649, encodeId=44af1e45649d2, content=<a href='/topic/show?id=dfa462913ba' target=_blank style='color:#2F92EE;'>#椭圆形瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62913, encryptionId=dfa462913ba, topicName=椭圆形瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc0635532325, createdName=drj2015, createdTime=Fri Oct 18 07:03:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000736, encodeId=2fd22000e3637, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 16 07:03:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393224, encodeId=e622139322490, content=<a href='/topic/show?id=34aae3121a7' target=_blank style='color:#2F92EE;'>#瞳孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73121, encryptionId=34aae3121a7, topicName=瞳孔)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Wed Mar 27 13:03:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363597, encodeId=39b436359e95, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Mar 26 21:18:54 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363539, encodeId=02d9363539be, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 25 22:22:22 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-25 orangesking

    0

相关资讯

Histol Histopathol:海藻糖在眼科的重要作用

捷克科学院实验医学研究所的Cejka C和Kubinova S等人近日在Histol Histopathol杂志上发表了一篇综述论文,作者系统的阐述了海藻糖在眼科中的应用。

TOPCON中国眼科及视光设备公司成立 为中国眼疾患者提供解决方案

2019年1月23日,享誉全球的 TOPCON集团中国区全资子公司 -- TOPCON中国眼科及视光设备公司开业典礼在北京朝阳区金长安大厦举行,TOPCON集团日方代表及全体中国员工参加了活动并出席剪彩仪式。TOPCON中国眼科及视光设备公司致力于眼科医疗产品的研发及推广。TOPCON 此次全面进军中国,将凭借其在眼科领域的领航者地位,为改善中国眼科疾病患者的生活质量提供有效地帮助。 TOPCO

FDA批准LOTEMAX(氯替泼诺依碳酸盐眼用凝胶)用于治疗眼外科手术后的炎症和疼痛

全球领先的眼保健公司Bausch Health公司近日宣布美国FDA已经批准了0.38%的LOTEMAX(氯替泼诺依碳酸酯眼用凝胶),这是一种用于治疗术后炎症和眼部手术后疼痛的新型凝胶制剂。与0.5%的LOTEMAX相比,0.38%的LOTEMAX能够提供亚微米粒径,可以更快地溶出药物,对房水的渗透性也提高了两倍。

眼科分科过细?整合医学帮助眼科医生告别孤军作战

苏格兰有一个童谣:宫廷里的孩子玩的都是瓷娃娃,瓷娃娃打碎以后,把碎片全部捡起来,虽然能粘贴成一个完整的瓷娃娃,但实际上这已经不是原来的瓷娃娃了。这就类似于亚学科和整体学科之间的关系。

J Thorac Dis:肺移植后的眼科并发症

美国俄亥俄州阿克伦市克利夫兰诊所Akron General内科的Dhal U及Cole眼科研究所的Raju S等人近日在J Thorac Dis杂志上发表了一篇重要综述文章,作者系统论述了肺移植后的眼科并发症。

依视路聚焦“眼健康体验中心”,引领眼健康中国策

2月21日,为期三天的第19届中国(上海)国际眼镜业展览会(SIOF)在上海世博展览馆正式拉开序幕。依视路作为全球视光行业的领导品牌,以“眼健康中国策”为主题,携行业大咖探讨眼健康,带来专业的S-C-PP眼健康管理模式,发布蓝光防护新品实力亮相SIOF。 中国(上海)国际眼镜业展览会依视路展位 响应健康中国策,为更多人提供专业的视力服务在开幕式上,依视路大中华地区首席执行官杜马诺先生发表了“依视